Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Bevacizumab is a monoclonal antibody currently used for the treatment of colorectal cancer.
It works by preventing the formation of new blood vessels (angiogenesis). The drug has been
shown to inhibit vascular endothelial growth factor (VEGF) activity. Previous research showed
positive findings in other solid tumors that had metastasized. In this study, the
investigators are investigating the response of adding bevacizumab to conventional
chemotherapy for metastatic breast cancer patients.